Document is current
Any future updates will be listed below
-
Authors
Bouman, Piet M. http://orcid.org/0000-0003-2698-4004
van Dam, Maureen A.
Jonkman, Laura E.
Steenwijk, Martijn D.
Schoonheim, Menno M.
Geurts, Jeroen J. G.
Hulst, Hanneke E.
-
Funding
Funding for this research was provided by:
Amsterdam University Medical Centers
- License Information
-
More Information
Article History
Received: 22 September 2023
Revised: 25 December 2023
Accepted: 2 January 2024
First Online: 30 January 2024
Declarations
:
: PMB has received research support from the Dutch Multiple Sclerosis Research Foundation, Grant no. 19-1049. MvD has nothing to disclose. LEJ has nothing to disclose. MDS has nothing to disclose. MMS serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch Multiple Sclerosis Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (VIDI Frant 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay and Merck. JJG has served as a consultant for Merck-Serono, Biogen, Novartis, Genzyma, and Teva Pharmaceuticals; he has received research support from the Dutch Multiple Sclerosis Research Foundation, Ammodo, Eurostars-EUREKA, Biogen, Celgene/Bristol Meyers Squibb, Merck, MedDay, and Novartis. HEH is an editor of the Multiple Sclerosis Journal controversies section, received research support from the Dutch Multiple Sclerosis Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck.
